Zum Hauptinhalt springen
Dekorationsartikel gehören nicht zum Leistungsumfang.
Schizophrenia
Buch von Daniel R Weinberger (u. a.)
Sprache: Englisch

225,95 €*

inkl. MwSt.

Versandkostenfrei per Post / DHL

Lieferzeit 1-2 Wochen

Kategorien:
Beschreibung
Schizophrenia is one of the most complex and disabling diseases to affect mankind. Relatively little is known about its nature and its origins, and available treatments are inadequate for most patients. As a result, there are inevitable controversies about what causes it, how to diagnose it, and how best to treat it. However, in the past decade, there has been an explosion of new research, with dramatic discoveries involving genetic etiology and epidemiological risk factors. There has also been a catalog of new drugs coming to market, and controversy about the relative advantages and disadvantages of newer compared with older therapies. In addition, developing technologies in genomics, molecular biology and neuroimaging provide streams of new information.

This book represents a definitive, essential, and up-to-date reference text on schizophrenia. It extensively and critically digests and clarifies recent advances and places them within a clinical context. The Editors (one American and one British), highly respected clinical psychiatrists and researchers and acknowledged experts on schizophrenia, have again assembled an outstanding group of contributors from the USA, UK, Europe and Australia, It will be of value to practising psychiatrists and to trainees, as well as to clinical and neuroscience researchers interested in keeping up with this field or coming into it.

The book consists of four sections: descriptive aspects, biological aspects, physical treatments, and psychological and social aspects. It reviews the theoretical controversies over symptomatology, classification and aetiology (particularly pertinent as DSM-V is being developed), the relationship of schizophrenia to the other psychoses, the significance of positive and negative symptoms and pre-morbid personality. It describes a variety of approaches to integrating the vast research data about schizophrenia, including neurodevelopmental, genetic, pharmacological, brain imaging and psychological findings. The biological treatment section reviews the comparative efficacy of various drugs, the management of drug-resistant patients and both neurological and metabolic complications. The final section looks at psychological therapies, social outcomes, and the economics of schizophrenia.

Schizophrenia is one of the most complex and disabling diseases to affect mankind. Relatively little is known about its nature and its origins, and available treatments are inadequate for most patients. As a result, there are inevitable controversies about what causes it, how to diagnose it, and how best to treat it. However, in the past decade, there has been an explosion of new research, with dramatic discoveries involving genetic etiology and epidemiological risk factors. There has also been a catalog of new drugs coming to market, and controversy about the relative advantages and disadvantages of newer compared with older therapies. In addition, developing technologies in genomics, molecular biology and neuroimaging provide streams of new information.

This book represents a definitive, essential, and up-to-date reference text on schizophrenia. It extensively and critically digests and clarifies recent advances and places them within a clinical context. The Editors (one American and one British), highly respected clinical psychiatrists and researchers and acknowledged experts on schizophrenia, have again assembled an outstanding group of contributors from the USA, UK, Europe and Australia, It will be of value to practising psychiatrists and to trainees, as well as to clinical and neuroscience researchers interested in keeping up with this field or coming into it.

The book consists of four sections: descriptive aspects, biological aspects, physical treatments, and psychological and social aspects. It reviews the theoretical controversies over symptomatology, classification and aetiology (particularly pertinent as DSM-V is being developed), the relationship of schizophrenia to the other psychoses, the significance of positive and negative symptoms and pre-morbid personality. It describes a variety of approaches to integrating the vast research data about schizophrenia, including neurodevelopmental, genetic, pharmacological, brain imaging and psychological findings. The biological treatment section reviews the comparative efficacy of various drugs, the management of drug-resistant patients and both neurological and metabolic complications. The final section looks at psychological therapies, social outcomes, and the economics of schizophrenia.

Über den Autor
Daniel R. Weinberger, Director: Genes, Cognition and Psychosis Program, National Institute of Mental Health, National Institute of Health, Bethesda, USA

Paul J. Harrison, University Department of Psychiatry, Warneford Hospital, Oxford, UK

Inhaltsverzeichnis

Contributors vii

Editor's Note xi

Preface to the 3 Rd Edition xii

Preface to the First Edition xiii

Part 1 Descriptive Aspects 1

1 Concept of schizophrenia: past present and future 3
Nancy C. Andreasen

2 The schizophrenia construct: symptomatic presentation 9
Celso Arango and William T. Carpenter

3 Child and adolescent schizophrenia 24
Chris Hollis and Judith Rapoport

4 Late-onset schizophrenia 47
Robert Howard and Dilip Jeste

5 The schizophrenia spectrum personality disorders 62
Eran Chemerinski and Larry J. Siever

6 The prodrome of schizophrenia 91
Jean Addington and Shôn W. Lewis

7 Course and outcome 104
Wolfram an der Heiden and Heinz Häfner

8 Neurocognitive impairments in schizophrenia: their character and role in symptom formation 142
Terry E. Goldberg Anthony David and James. M. Gold

Part 2 Biological Aspects 163

9 The secondary schizophrenias 165
Thomas M. Hyde and Maria A. Ron

10 Schizophrenia: the epidemiological horizon 185
Assen Jablensky James B. Kirkbride and Peter B. Jones

11 Environmental risk factors for schizophrenia 226
John J. McGrath and Robin M. Murray

12 Classical genetic studies of schizophrenia 245
Brien Riley and Kenneth S. Kendler

13 Genetic associations in schizophrenia 269
Michael C. O'Donovan and Michael J. Owen

14 Intermediate phenotypes in genetic studies of schizophrenia 289
Michael F. Egan and Tyrone D. Cannon

15 Electrophysiology of schizophrenia 311
Georg Winterer and Robert W. McCarley

16 Structural brain imaging in schizophrenia and related populations 334
Stephen M. Lawrie and Christos Pantelis

17 Functional brain imaging in schizophrenia 353
Andreas Meyer-Lindenberg and Edward T. Bullmore

18 Neuropathology of schizophrenia 372
Paul J. Harrison David A. Lewis and Joel E. Kleinman

19 Neurodevelopmental origins of schizophrenia 393
Daniel R. Weinberger and Pat Levitt

20 Dopamine and schizophrenia 413
Anissa Abi-Dargham and Anthony A. Grace

21 Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia 433
John H. Krystal and Bita Moghaddam

22 Animal models of schizophrenia 462
Barbara K. Lipska and Joseph A. Gogos

Part 3 Physical Treatments 483

23 Pharmacology and neuroscience of antipsychotic drugs 485
John L. Waddington Colm M.P. O'Tuathaigh and Gary J. Remington

24 Principles of pharmacological treatment in schizophrenia 515
Thomas R.E. Barnes and Stephen R. Marder

25 Comparative efficacy and effectiveness in the drug treatment of schizophrenia 525
John R. Geddes T. Scott Stroup and Jeffrey A. Lieberman

26 Approaches to treatment-resistant patients 540
Stephan Leucht Christoph U. Correll and John M. Kane

27 Neurological complications of antipsychotic drugs 561
Peter M. Haddad and Venkata S. Mattay

28 Metabolic adverse effects associated with antipsychotic medications 577
John W. Newcomer and Stefan Leucht

Part 4 Psychosocial Aspects 599

29 Schizophrenia and psychosocial stresses 601
Paul E. Bebbington and Elizabeth Kuipers

30 Mental health services for patients with schizophrenia 625
Tom Burns and Bob Drake

31 Societal outcomes in schizophrenia 644
Iain Kooyman and Elizabeth Walsh

32 Psychological treatment of psychosis 666
Gillian Haddock and Will Spaulding

33 Economics of the treatment of schizophrenia 687
Nancy H. Covell Susan M. Essock and Linda K. Frisman

Index 701

Colour plates are found facing page 338

Details
Erscheinungsjahr: 2011
Fachbereich: Andere Fachgebiete
Genre: Importe, Medizin
Rubrik: Wissenschaften
Medium: Buch
Inhalt: 736 S.
ISBN-13: 9781405176972
ISBN-10: 1405176970
Sprache: Englisch
Einband: Gebunden
Redaktion: Weinberger, Daniel R
Harrison, Paul
Herausgeber: Daniel R Weinberger/Paul Harrison
Auflage: 3rd Revised edition
Hersteller: Wiley
John Wiley & Sons
Verantwortliche Person für die EU: Wiley-VCH GmbH, Boschstr. 12, D-69469 Weinheim, amartine@wiley-vch.de
Maße: 284 x 233 x 40 mm
Von/Mit: Daniel R Weinberger (u. a.)
Erscheinungsdatum: 21.02.2011
Gewicht: 2,268 kg
Artikel-ID: 107154620
Über den Autor
Daniel R. Weinberger, Director: Genes, Cognition and Psychosis Program, National Institute of Mental Health, National Institute of Health, Bethesda, USA

Paul J. Harrison, University Department of Psychiatry, Warneford Hospital, Oxford, UK

Inhaltsverzeichnis

Contributors vii

Editor's Note xi

Preface to the 3 Rd Edition xii

Preface to the First Edition xiii

Part 1 Descriptive Aspects 1

1 Concept of schizophrenia: past present and future 3
Nancy C. Andreasen

2 The schizophrenia construct: symptomatic presentation 9
Celso Arango and William T. Carpenter

3 Child and adolescent schizophrenia 24
Chris Hollis and Judith Rapoport

4 Late-onset schizophrenia 47
Robert Howard and Dilip Jeste

5 The schizophrenia spectrum personality disorders 62
Eran Chemerinski and Larry J. Siever

6 The prodrome of schizophrenia 91
Jean Addington and Shôn W. Lewis

7 Course and outcome 104
Wolfram an der Heiden and Heinz Häfner

8 Neurocognitive impairments in schizophrenia: their character and role in symptom formation 142
Terry E. Goldberg Anthony David and James. M. Gold

Part 2 Biological Aspects 163

9 The secondary schizophrenias 165
Thomas M. Hyde and Maria A. Ron

10 Schizophrenia: the epidemiological horizon 185
Assen Jablensky James B. Kirkbride and Peter B. Jones

11 Environmental risk factors for schizophrenia 226
John J. McGrath and Robin M. Murray

12 Classical genetic studies of schizophrenia 245
Brien Riley and Kenneth S. Kendler

13 Genetic associations in schizophrenia 269
Michael C. O'Donovan and Michael J. Owen

14 Intermediate phenotypes in genetic studies of schizophrenia 289
Michael F. Egan and Tyrone D. Cannon

15 Electrophysiology of schizophrenia 311
Georg Winterer and Robert W. McCarley

16 Structural brain imaging in schizophrenia and related populations 334
Stephen M. Lawrie and Christos Pantelis

17 Functional brain imaging in schizophrenia 353
Andreas Meyer-Lindenberg and Edward T. Bullmore

18 Neuropathology of schizophrenia 372
Paul J. Harrison David A. Lewis and Joel E. Kleinman

19 Neurodevelopmental origins of schizophrenia 393
Daniel R. Weinberger and Pat Levitt

20 Dopamine and schizophrenia 413
Anissa Abi-Dargham and Anthony A. Grace

21 Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia 433
John H. Krystal and Bita Moghaddam

22 Animal models of schizophrenia 462
Barbara K. Lipska and Joseph A. Gogos

Part 3 Physical Treatments 483

23 Pharmacology and neuroscience of antipsychotic drugs 485
John L. Waddington Colm M.P. O'Tuathaigh and Gary J. Remington

24 Principles of pharmacological treatment in schizophrenia 515
Thomas R.E. Barnes and Stephen R. Marder

25 Comparative efficacy and effectiveness in the drug treatment of schizophrenia 525
John R. Geddes T. Scott Stroup and Jeffrey A. Lieberman

26 Approaches to treatment-resistant patients 540
Stephan Leucht Christoph U. Correll and John M. Kane

27 Neurological complications of antipsychotic drugs 561
Peter M. Haddad and Venkata S. Mattay

28 Metabolic adverse effects associated with antipsychotic medications 577
John W. Newcomer and Stefan Leucht

Part 4 Psychosocial Aspects 599

29 Schizophrenia and psychosocial stresses 601
Paul E. Bebbington and Elizabeth Kuipers

30 Mental health services for patients with schizophrenia 625
Tom Burns and Bob Drake

31 Societal outcomes in schizophrenia 644
Iain Kooyman and Elizabeth Walsh

32 Psychological treatment of psychosis 666
Gillian Haddock and Will Spaulding

33 Economics of the treatment of schizophrenia 687
Nancy H. Covell Susan M. Essock and Linda K. Frisman

Index 701

Colour plates are found facing page 338

Details
Erscheinungsjahr: 2011
Fachbereich: Andere Fachgebiete
Genre: Importe, Medizin
Rubrik: Wissenschaften
Medium: Buch
Inhalt: 736 S.
ISBN-13: 9781405176972
ISBN-10: 1405176970
Sprache: Englisch
Einband: Gebunden
Redaktion: Weinberger, Daniel R
Harrison, Paul
Herausgeber: Daniel R Weinberger/Paul Harrison
Auflage: 3rd Revised edition
Hersteller: Wiley
John Wiley & Sons
Verantwortliche Person für die EU: Wiley-VCH GmbH, Boschstr. 12, D-69469 Weinheim, amartine@wiley-vch.de
Maße: 284 x 233 x 40 mm
Von/Mit: Daniel R Weinberger (u. a.)
Erscheinungsdatum: 21.02.2011
Gewicht: 2,268 kg
Artikel-ID: 107154620
Sicherheitshinweis